

Summary of changes to specifications for AUA AQUA measures for PY2024

Measure	Title (PY2024 version)	2023 Measure Specification	Changes made to 2024 measure specification
AQUA14	Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment	N/A	No changes
AQUA15	Stones: Urinalysis or Urine Culture Performed Before Surgical Stone Procedures	Title, description, and numerator statements	For additional clarity, explicitly included “urine culture” in these statements (this does not affect the measure calculation because documented urine culture met the PY2023 version of the measure)
		Denominator	Patients with CPT code 52332 are now included in the denominator only if they have a stones diagnosis on the day of the procedure
AQUA16	Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease	N/A	No changes
AQUA18	N/A	N/A	This measure has been replaced by AQUA35
AQUA26	Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH	Exceptions: Patients with known renal insufficiency or with documented flank pain/hematuria within 30 days of dx; patients with urinary retention; etc.	Made minor wording changes to clarify that the 30-day timeframe applies to the urinary retention exception (this does not affect the measure calculation)
AQUA8	Hospital admissions or infectious complications within 30 days of prostate biopsy	Numerator: Patients with urinary retention, infection, new antibiotic prescription 1-30 days post-biopsy, or inpatient consult within 30 days, or infection or sepsis requiring hospitalization within 30 days	Added guidance to ensure that chronic urinary retention, as indicated by a diagnosis in the year prior to biopsy, is not erroneously counted as a complication of biopsy
AQUA35 (previously AUA01)	Non-Muscle Invasive Bladder Cancer: Initial Management/Surveillance for Non-Muscle Invasive Bladder Cancer	Numerator: Cystoscopy	Added one new CPT code newly approved for use for 2024

Measure	Title (PY2024 version)	2023 Measure Specification	Changes made to 2024 measure specification
AQUA36 (previously AUA02)	Prostate Cancer: Confirmation Biopsy in Newly Diagnosed Patients on Active Surveillance	Denominator: Patients aged 30-80 with new diagnosis of low risk prostate cancer who are on active surveillance	Changed age range from patients aged <b>30-80</b> to patients aged <b>30-75</b> ; added one new SNOMED code
		Exclusions: Patients with prior treatment for prostate cancer; patients on watchful waiting	Dropped these as formal exclusions, as these patients should not be flagged as newly diagnosed patients on active surveillance (i.e., they should not be included in the initial patient population and thus would not need to be excluded)
		Exceptions: None	Added exception for any treatment of prostate cancer within 12 month post-diagnosis
MUSIC4	Prostate Cancer: Active Surveillance/Watchful Waiting for Newly Diagnosed Low Risk Prostate Cancer Patients	Denominator: Newly diagnosed low-risk prostate cancer patients age 30 or older	Added one new SNOMED code
		Numerator: Patients on active surveillance or watchful waiting	Revised numerator statement to: Patients on active surveillance or watchful waiting (no evidence of radical therapy post-diagnosis). Instead of relying on the clinician note to determine active surveillance/watchful waiting status, will rely on documentation of radical therapy in the 12 months post-diagnosis within a structured field (e.g., ICD, CPT, SNOMED codes) to indicate the patient is NOT on active surveillance or watchful waiting
		Exclusions: Patients who have had prior treatment for prostate cancer	Dropped these as formal exclusions, as these patients should not be flagged as newly diagnosed (i.e., they should not be included in the initial patient population and thus would not need to be excluded)